Scan to help plan treatment tapering for rheumatoid arthritis
Part of Bones, joints & muscles, Immune system & allergy, Skin clinical trials.
This study tests whether a special scan can help doctors decide if you can safely reduce your rheumatoid arthritis medication. It may help you taper your treatment while keeping your disease under control.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a diagnosis of rheumatoid arthritis.
- You are in remission or have low disease activity, and your doctor thinks you might be able to reduce your medication.
- You have been on a TNF inhibitor (like adalimumab, etanercept, certolizumab, golimumab, or infliximab) for at least 6 months at a stable dose.
- You are between 18 and 80 years old.
- You are not pregnant, not breastfeeding, and have no severe kidney or liver problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1 study uses special imaging to look at lymph vessels in people with rheumatoid arthritis (RA). The goal is to better understand changes in the lymph system in early versus long-standing RA and during certain treatments.
This study uses a special “light tracer” medicine with adalimumab to see where inflammation is in the gut (IBD) or joints (RA). If you have active disease, it may help doctors better target treatment by showing inflammation more clearly during scans.
This study uses a special heart CT scan to look for early signs of heart disease in people with rheumatoid arthritis. It may help find problems before symptoms start.
This trial tests a step-by-step plan for treating rheumatoid arthritis when current medicines aren’t controlling the disease. It compares how well a targeted approach works by adjusting treatment for people who need a TNF inhibitor.
This study compares two different schedules for reducing prednisone (a steroid) in people with rheumatoid arthritis who are also taking another standard arthritis medicine. The goal is to find the safest and most effective way to taper off steroids without causing a flare-up.
This trial tests a new medicine called CIT-013 for people with rheumatoid arthritis. It aims to see if CIT-013 can help reduce joint swelling and pain when added to your current treatment.
Hear when a new Rheumatoid arthritis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.